Stem definition | Drug id | CAS RN |
---|---|---|
2637 | 50-52-2 |
Dose | Unit | Route |
---|---|---|
0.30 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 1 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 35.89 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 40 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
March 15, 1962 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Overdose | 50.88 | 35.57 | 26 | 640 | 101953 | 46583443 |
Coma | 38.39 | 35.57 | 18 | 648 | 58331 | 46627065 |
Tachycardia | 37.27 | 35.57 | 21 | 645 | 99601 | 46585795 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Antipsychotic drug level below therapeutic | 186.99 | 55.00 | 34 | 1101 | 1338 | 29950005 |
Therapeutic product effect variable | 186.57 | 55.00 | 34 | 1101 | 1355 | 29949988 |
Obsessive-compulsive disorder | 182.50 | 55.00 | 40 | 1095 | 4101 | 29947242 |
Disinhibition | 174.94 | 55.00 | 34 | 1101 | 1923 | 29949420 |
Euphoric mood | 148.34 | 55.00 | 34 | 1101 | 4256 | 29947087 |
Increased appetite | 139.22 | 55.00 | 34 | 1101 | 5583 | 29945760 |
Akathisia | 137.54 | 55.00 | 34 | 1101 | 5870 | 29945473 |
Suicide attempt | 89.69 | 55.00 | 38 | 1097 | 36659 | 29914684 |
Therapeutic product effect incomplete | 79.21 | 55.00 | 34 | 1101 | 33800 | 29917543 |
Dyslipidaemia | 75.43 | 55.00 | 21 | 1114 | 5706 | 29945637 |
Leukopenia | 71.33 | 55.00 | 37 | 1098 | 56122 | 29895221 |
Obesity | 71.32 | 55.00 | 22 | 1113 | 8533 | 29942810 |
Weight increased | 56.22 | 55.00 | 35 | 1100 | 74878 | 29876465 |
Source | Code | Description |
---|---|---|
ATC | N05AC02 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperidine structure |
FDA CS | M0016525 | Phenothiazines |
FDA EPC | N0000175746 | Phenothiazine |
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018492 | Dopamine Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
CHEBI has role | CHEBI:37890 | alpha-adrenoceptor antagonists |
CHEBI has role | CHEBI:37955 | h1-receptor blockers |
CHEBI has role | CHEBI:48279 | serotonin antagonists |
CHEBI has role | CHEBI:48561 | dopamine blocker |
CHEBI has role | CHEBI:65190 | typical antipsychotic drug |
CHEBI has role | CHEBI:76779 | prolyl oligopeptidase (ec 3.4.21.26) inhibitor |
CHEBI has role | CHEBI:77402 | trypanothione reductase inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Treatment-Resistant Schizophrenia | indication | ||
Hyperkalemia | contraindication | 14140009 | |
Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
Senile dementia | contraindication | 15662003 | |
Orthostatic hypotension | contraindication | 28651003 | |
Hypokalemia | contraindication | 43339004 | |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Stupor | contraindication | 89458003 | |
Tardive dyskinesia | contraindication | 102449007 | |
Prolonged QT interval | contraindication | 111975006 | |
Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
Coma | contraindication | 371632003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Congenital long QT syndrome | contraindication | 442917000 | |
Predisposed to Torsades de Pointes Cardiac Arrhythmias | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.22 | Basic |
pKa2 | 3.45 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | ANTAGONIST | IC50 | 7.40 | WOMBAT-PK | CHEMBL | |||
Histamine H4 receptor | GPCR | Ki | 5.62 | PDSP | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.77 | PDSP | |||||
5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.44 | PDSP | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 8.62 | PDSP | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 5.90 | PDSP | |||||
5-hydroxytryptamine receptor 1E | GPCR | Ki | 6.71 | PDSP | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 6.96 | PDSP | |||||
5-hydroxytryptamine receptor 1D | GPCR | Ki | 6.24 | PDSP | |||||
Histamine H2 receptor | GPCR | Ki | 6.87 | PDSP | |||||
D(4) dopamine receptor | GPCR | ANTAGONIST | Ki | 7.98 | PDSP | ||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 7.60 | PDSP | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 7.13 | PDSP | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 6.47 | PDSP | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8.57 | PDSP | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.87 | PDSP | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.89 | PDSP | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 8.05 | PDSP | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.85 | PDSP | |||||
5-hydroxytryptamine receptor 2C | GPCR | ANTAGONIST | Ki | 7.30 | IUPHAR | ||||
5-hydroxytryptamine receptor 6 | GPCR | ANTAGONIST | Ki | 7.20 | IUPHAR | ||||
Histamine H1 receptor | GPCR | ANTAGONIST | Ki | 7.70 | IUPHAR | ||||
5-hydroxytryptamine receptor 1A | GPCR | ANTAGONIST | Ki | 7.10 | IUPHAR | ||||
D(1B) dopamine receptor | GPCR | ANTAGONIST | Ki | 5.60 | IUPHAR | ||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.82 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.81 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.09 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 5.75 | DRUG MATRIX | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 8.69 | DRUG MATRIX | |||||
Kappa-type opioid receptor | GPCR | Ki | 6.00 | DRUG MATRIX | |||||
Cytochrome P450 1A2 | Enzyme | IC50 | 5.03 | DRUG MATRIX | |||||
Epidermal growth factor receptor | Kinase | IC50 | 5.53 | DRUG MATRIX | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 5.20 | DRUG MATRIX | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.30 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | EC50 | 8 | WOMBAT-PK | ||||
Aldehyde oxidase | Enzyme | IC50 | 6.80 | WOMBAT-PK | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 7.90 | WOMBAT-PK | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 7 | WOMBAT-PK | |||||
D(1A) dopamine receptor | GPCR | IC50 | 7.10 | WOMBAT-PK | |||||
Nuclear receptor subfamily 1 group I member 3 | Nuclear hormone receptor | WOMBAT-PK | |||||||
Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 5.19 | CHEMBL | |||||
Serine/threonine-protein kinase pim-1 | Kinase | IC50 | 5.16 | CHEMBL | |||||
5-hydroxytryptamine receptor 7 | GPCR | Ki | 7.15 | CHEMBL | |||||
D(3) dopamine receptor | GPCR | ANTAGONIST | IC50 | 7.30 | WOMBAT-PK | ||||
Alpha-1B adrenergic receptor | GPCR | Ki | 8.59 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 6.28 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor | GPCR | IC50 | 8.70 | CHEMBL | |||||
Serotonin 2 (5-HT2) receptor | GPCR | IC50 | 7.74 | CHEMBL | |||||
Dopamine receptor | GPCR | IC50 | 7.07 | CHEMBL | |||||
Adrenergic receptor alpha-2 | GPCR | IC50 | 5.89 | CHEMBL | |||||
Pleiotropic ABC efflux transporter of multiple drugs | Transporter | IC50 | 5.89 | CHEMBL | |||||
Serotonin 1 (5-HT1) receptor | GPCR | IC50 | 5.06 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | IC50 | 7.76 | CHEMBL | |||||
Histamine H1 receptor | GPCR | IC50 | 7 | CHEMBL | |||||
D(2) dopamine receptor | GPCR | IC50 | 8.55 | CHEMBL | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 8.29 | CHEMBL | |||||
5-hydroxytryptamine receptor 6 | GPCR | ANTAGONIST | Ki | 8.20 | IUPHAR | ||||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 7.20 | IUPHAR | ||||
G protein-activated inward rectifier potassium channel 2 | Ion channel | GATING INHIBITOR | EC50 | 4.20 | IUPHAR |
ID | Source |
---|---|
4019946 | VUID |
N0000148031 | NUI |
D00373 | KEGG_DRUG |
130-61-0 | SECONDARY_CAS_RN |
4017892 | VANDF |
4019946 | VANDF |
C0591768 | UMLSCUI |
CHEBI:9566 | CHEBI |
LZU | PDB_CHEM_ID |
CHEMBL479 | ChEMBL_ID |
CHEMBL1200916 | ChEMBL_ID |
D013881 | MESH_DESCRIPTOR_UI |
5452 | PUBCHEM_CID |
818 | INN_ID |
DB00679 | DRUGBANK_ID |
N3D6TG58NI | UNII |
100 | IUPHAR_LIGAND_ID |
10502 | RXNORM |
1788 | MMSL |
2125 | MMSL |
5571 | MMSL |
5572 | MMSL |
d00389 | MMSL |
001482 | NDDF |
004591 | NDDF |
18550006 | SNOMEDCT_US |
33588000 | SNOMEDCT_US |
372706001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0612 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0614 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 15 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0616 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 15 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0618 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 15 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-565 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-566 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 15 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-567 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 15 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-580 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 15 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53489-148 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 18 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53489-149 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 18 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53489-150 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 18 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53489-500 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 18 sections |
Thioridazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1706 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 15 sections |